Artelo Biosciences (ARTL) vs Curis (CRIS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Artelo Biosciences is the larger company by market cap ($1.8 million vs $1.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARTL | CRIS |
|---|---|---|
| Share price | $3.37 | $0.7094 |
| Market cap | $1.85M | $1.72M |
| 1-day change | -1.17% | -3.69% |
| P/E ratio (TTM) | — | 0.54 |
| EPS (TTM) | $-136.26 | $1.32 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $179.19 | $33.60 |
| 52-week low | $3.33 | $0.61 |
| Distance from 52-week high | -98.12% | -97.89% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +5914.94% |
| Average volume | 480.72K | 199.15K |
| Shares outstanding | 547.77K | 2.43M |
| Employees | 7 | 20 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Artelo Biosciences
ARTL stock →Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of cancer-related anorexia; and ART12.11, a cocrystal composition of cannabidiol and tetramethylpyrazine for the treatment anxiety, depression, post-traumatic stress disorder PTSD, epilepsy and insomnia, and other potential indications.
Healthcare · Biotechnology · 7 employees
About Curis
CRIS stock →Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed/refractory primary central nervous system lymphoma.
Healthcare · Biotechnology · 20 employees
ARTL vs CRIS FAQ
Which is bigger, Artelo Biosciences or Curis?
Artelo Biosciences (ARTL) is larger, with a market capitalization of $1.85M compared with $1.72M for Curis (CRIS).
Are Artelo Biosciences and Curis in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.